drugset / Trial / NCT00249912

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

NCT00249912

Phase 3 Completed 415 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with rosuvastatin on cholesterol levels in treating patients with elevated cholesterol.

Timeline

Start
2005-10
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapaquistat acetate Small molecule 50 mg Oral
Subject Lapaquistat acetate Small molecule 100 mg Oral
Comparator Rosuvastatin Small molecule 10 mg
Comparator Rosuvastatin Small molecule 20 mg

Indications